Full-Time
Buying Channel Orchestration & Enablement Specialist
Vertex Pharmaceuticals
5,001-10,000 employees
Develops therapies for serious genetic diseases
No salary listed
Company Does Not Provide H1B Sponsorship
Boston, MA, USA
Hybrid
Hybrid work allows remote work up to two days per week, or employees may choose to work on-site five days per week.
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Vertex Pharmaceuticals
See people who can refer or advise you
- A bachelor's degree is required.
- At least 4 years of experience in procurement, Procure-to-Pay, sourcing operations, buying channel enablement, or related roles is required.
- Experience working with procurement platforms such as Coupa, including catalogs, guided buying, and supplier enablement, is required.
- Experience with intake and orchestration tools such as Zip, ORO, or similar workflow-based platforms is required.
- Strong understanding of procurement processes and user-facing workflows is required.
- The ability to translate business needs into system-enabled workflows without owning the technical build is required.
- Strong collaboration, communication, and stakeholder management skills are required.
- The ability to work effectively in a cross-functional, process-driven environment with attention to detail and execution quality is required.
- Knowledge of procurement processes across Source-to-Pay and Procure-to-Pay activities is required.
- Knowledge of policy-aligned channel design and compliance enablement is required.
- Experience improving user journeys and processes is required.
- The ability to translate business requirements into workflow configurations is required.
- Experience tracking performance, providing reporting inputs, and supporting continuous improvement is required.
- Support the design, configuration, and continuous optimization of procurement buying channels, including catalogs, preferred suppliers, guided buying paths, and request channels.
- Ensure buying channel designs guide users to the appropriate procurement pathway based on category, supplier, policy, and business need.
- Align buying channels to category strategies, preferred supplier programs, and procurement policy requirements.
- Help standardize buying experiences to improve usability, consistency, and compliance across the organization.
- Configure and manage intake and orchestration business rules within platforms such as Zip, ORO, or similar tools.
- Ensure intake requests are routed efficiently with the right approvals, workflows, and policy guardrails.
- Refine routing logic, intake rules, forms, and user journeys to improve user experience and process compliance.
- Partner with stakeholders to ensure intake experiences support procurement objectives and business needs.
- Support the business owner with the configuration of buying channels and intake workflows in tools such as Coupa and orchestration platforms.
- Translate business requirements into workflows, forms, routing logic, and user experiences.
- Partner with Digital and Information Technology on technical updates while maintaining ownership of process design and business configuration requirements.
- Support testing, validation, and process readiness for workflow or channel changes.
- Identify friction points across buying channels and intake workflows and drive practical improvements.
- Support training materials, user documentation, and change management efforts to improve adoption of preferred procurement channels.
- Monitor user behavior, channel usage, and workflow outcomes to ensure alignment with intended processes.
- Simplify complex procurement processes into intuitive and user-friendly experiences.
- Reinforce procurement policies, including preferred supplier use, approved workflows, and No PO, No Pay requirements.
- Help reduce maverick spend by guiding users through compliant and optimized buying pathways.
- Partner with Governance and Category teams to maintain alignment between procurement policy and channel execution.
- Enforce business rules that improve compliance without creating unnecessary complexity.
- Track channel effectiveness through metrics such as adoption rates, cycle times, compliance levels, and workflow efficiency.
- Identify improvement opportunities and recommend enhancements that simplify and standardize the buying experience.
- Partner with Analytics teams to support reporting, dashboards, and insights on buying channel and intake performance.
- Contribute to ongoing process improvement efforts across the Source-to-Pay lifecycle.
- Experience in a Center of Excellence, procurement transformation, or process excellence environment.
- Familiarity with guided buying, intake management, and procurement orchestration design.
- Experience supporting preferred supplier programs and buying channel strategies.
- Exposure to Contract Lifecycle Management, Third-Party Risk Management, or Procure-to-Pay integration points across the Source-to-Pay lifecycle.
- Experience working in regulated environments with strong compliance expectations.
- Experience supporting training, adoption, and change management for procurement tools and workflows.
Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1989
Get referred to Vertex Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Vertex raised 2026 revenue guidance to $13.1-$13.2 billion after Q2 growth.
- Povetacicept has a November 30, 2026 PDUFA date, opening nephrology revenue.
- JOURNAVX hit $50 million in Q2 2026, while CASGEVY grew 151% year over year.
What critics are saying
- Sionna axed SION-719 on August 10, 2026, but CF competition keeps advancing.
- Zimislecel faced a voluntary manufacturing pause in 2026, exposing cell-therapy execution risk.
- Crinetics adds $8.8 billion integration risk; a failed close leaves Vertex overdependent on CF.
What makes Vertex Pharmaceuticals unique
- Vertex still owns CFTR modulators; Q2 2026 CF revenue reached $3.2 billion.
- Vertex broadened beyond CF with CASGEVY, JOURNAVX, and Crinetics, announced July 2026.
- Vertex moves fast: CASGEVY pediatric FDA approval arrived 53 days after filing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 8%1 year growth
↑ 8%2 year growth
↑ 8%Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]
Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.
Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.
Sionna Therapeutics is challenging Vertex Pharmaceuticals' dominance in the cystic fibrosis (CF) drug market. Vertex, valued at nearly $123 billion, generated $3.2 billion in CF-related sales in Q2, representing most of its $3.33 billion total revenue. Sionna, worth $2.2 billion, claims its approach could restore normal function to the CFTR protein, which causes CF when misfolded. Vertex's current treatments improve the protein's shape and function but don't restore normal function for most patients. Vertex generates over $12 billion annually from CF treatments. However, several companies, including AbbVie, have previously attempted to challenge Vertex's market position without success. Vertex has maintained its position since receiving its first CF drug approval in 2012.